These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36250667)

  • 1. Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS.
    Rymer JA; Kaltenbach LA; Peterson ED; Cohen DJ; Fonarow GC; Choudhry NK; Henry TD; Cannon CP; Wang TY
    J Am Heart Assoc; 2022 Oct; 11(20):e026421. PubMed ID: 36250667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Anstrom KJ; Fonarow GC; Henry TD; Cannon CP; Choudhry NK; Cohen DJ; Atreja N; Bhalla N; Eudicone JM; Wang TY
    Circ Cardiovasc Qual Outcomes; 2020 May; 13(5):e006182. PubMed ID: 32393129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs.
    Doll JA; Kaltenbach LA; Anstrom KJ; Cannon CP; Henry TD; Fonarow GC; Choudhry NK; Fonseca E; Bhalla N; Eudicone JM; Peterson ED; Wang TY
    J Am Heart Assoc; 2020 Apr; 9(8):e014975. PubMed ID: 32299284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    Wang TY; Kaltenbach LA; Cannon CP; Fonarow GC; Choudhry NK; Henry TD; Cohen DJ; Bhandary D; Khan ND; Anstrom KJ; Peterson ED
    JAMA; 2019 Jan; 321(1):44-55. PubMed ID: 30620370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
    Doll JA; Wang TY; Choudhry NK; Cannon CP; Cohen DJ; Fonarow GC; Henry TD; Bhandary DD; Khan N; Davidson-Ray LD; Anstrom K; Peterson ED
    Am Heart J; 2016 Jul; 177():33-41. PubMed ID: 27297847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 May; 5(5):532-539. PubMed ID: 32129795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial.
    Rymer JA; Wegermann ZK; Kaltenbach LA; Webb LE; Peterson ED; Wang TY
    J Am Heart Assoc; 2023 Jun; 12(12):e029063. PubMed ID: 37301758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of pre- and posthospital medication adherence in myocardial infarction patients.
    Doll JA; Hellkamp AS; Thomas L; Fonarow GC; Peterson E; Wang TY
    Am Heart J; 2019 Feb; 208():74-80. PubMed ID: 30580129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Change in Employment Status After Acute Myocardial Infarction: Analysis From the TRANSLATE-ACS Study.
    Warraich HJ; Kaltenbach LA; Fonarow GC; Peterson ED; Wang TY
    Circ Cardiovasc Qual Outcomes; 2018 Jun; 11(6):e004528. PubMed ID: 29895612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
    Bonaca MP; Bhatt DL; Steg PG; Storey RF; Cohen M; Im K; Oude Ophuis T; Budaj A; Goto S; López-Sendón J; Diaz R; Dalby A; Van de Werf F; Ardissino D; Montalescot G; Aylward P; Magnani G; Jensen EC; Held P; Braunwald E; Sabatine MS
    Eur Heart J; 2016 Apr; 37(14):1133-42. PubMed ID: 26491109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome).
    Fosbøl EL; Ju C; Anstrom KJ; Zettler ME; Messenger JC; Waksman R; Effron MB; Baker BA; Cohen DJ; Peterson ED; Wang TY
    Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27789517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease.
    Rymer JA; Kaltenbach LA; Doll JA; Messenger JC; Peterson ED; Wang TY
    J Am Heart Assoc; 2019 May; 8(10):e012236. PubMed ID: 31070112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study.
    Tajchman DH; Nabi H; Aslam M; Butt JH; Grove EL; Engstrøm T; Holmvang L; Fosbøl EL; Køber L; Sørensen R
    Eur Heart J Acute Cardiovasc Care; 2021 Oct; 10(7):774-786. PubMed ID: 34570197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-practice gaps in P2Y
    Falster MO; Schaffer AL; Wilson A; Nasis A; Jorm LR; Hay M; Leeb K; Pearson SA; Brieger D
    Intern Med J; 2022 Feb; 52(2):249-258. PubMed ID: 32840951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention in Patients Treated With Potent P2Y12 inhibitors - a VALIDATE-SWEDEHEART Substudy.
    Bergman S; Mohammad MA; James SK; Angerås O; Wagner H; Jensen J; Scherstén F; Fröbert O; Koul S; Erlinge D
    J Am Heart Assoc; 2021 Sep; 10(18):e022984. PubMed ID: 34514849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
    Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK
    Kardiologiia; 2022 Sep; 62(9):44-53. PubMed ID: 36206137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.